Search for a trial

Ex vivo activation characterization and targeting of the latent HIV infected reservoir to cure HIV

1. Ex vivo stimulation of HIV genome expression in latently infected peripheral blood mononuclear cells (PBMC's) from patients on cART using new and established compounds.2. To characterize latently HIV-1 infected peripheral blood mononuclear…

An Open-Label Study Evaluating Anti-Viral Effects of Voclosporin in SARS-CoV-2 Positive Kidney Transplant Recipients - the VOCOVID Study

Primary Objective: To investigate the kinetics of the anti-viral effects of VCS, compared to standard of care with TAC, on SARS-CoV-2 over 56 days, in stable KTRs.Secondary Objective: To assess the safety and tolerability of VCS in stable KTRs…

A randomized, double-blind, placebo-controlled, study evaluating the efficacy and safety of otilimab IV in patients with severe pulmonary COVID-19 related disease (study 214094)

Primary:Compare the efficacy of single IV injection with otilimab 90 mg in adults with severe pulmonary COVID-19 related disease.Secondary:Other aspects of efficacy. Safety and tolerability.

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Clinical Outcomes, Antiviral Activity, Safety, Tolerability, Pharmacokinetics, and Pharmacokinetics/Pharmacodynamics of JNJ-53718678 in Adult and Adolescent Hematopoietic Stem Cell Transplant Recipients with Respiratory Syncytial Virus Infection of the Upper Respiratory Tract

To evaluate the clinical outcomes, antiviral activity, safety, tolerability, PK, and PK/PD of JNJ 53718678 in adult (ie, adult cohort) and adolescent (ie, adolescent cohort) HSCT recipients with an RSV upper respiratory tract infection (URT)I.The…

A Phase IIIb, open-label, hybrid type III trial evaluating implementation strategies for long-acting cabotegravir plus long-acting rilpivirine every two months in HIV-1 infected, virologically suppressed adults in select European healthcare settings.

The overall objective of the CAB LA + RPV LA clinical development programme is to develop a highly effective, well-tolerated, two-drug, long-acting injectable regimen which has the potential to offer improved treatment convenience, compliance and…

A PHASE I, SPONSOR-OPEN, INVESTIGATORBLINDED,SUBJECT-BLINDED, MULTI-CENTER,
PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS
AND PHARMACODYNAMICS OF ORAL ADMINISTRATION OF RO7020531: (1). SINGLE
AND MULTIPLE ASCENDING DOSES IN HEALTHY MALE AND FEMALE SUBJECTS; (2). 6-WEEK
TREATMENT OF VIROLOGICALLY SUPPRESSED PATIENTS WITH CHRONIC HEPATITIS B VIRUS
INFECTION

OBJECTIVESPrimary ObjectivesThe primary objective is:* To assess the safety and tolerability of 6 weeks of treatment with RO7020531 administered orally to virologically suppressed chronic hepatitis B (CHB) patients.Secondary ObjectivesThe secondary…

Investigating the immune response to COVID-19 Vaccination in Lung Transplantation patients (COVALENT study)

To investigate the humoral and cellular immune response, and the development of immunological memory to the COVID-19 vaccination in lung transplantation patients. To clarify firstly if immunity develops in these patients and secondly, if the immune…

Monitoring immunogenicity of SARS-Cov-2 vaccination in Dutch middle-aged and older individuals
(participating in the Doetinchem Cohort Study)

The primary objective is to assess antibody responses against the SARS-CoV-2 vaccines in blood of individuals of 50-93 years of age at several timepoints post vaccination and post booster vaccinations, with respect to age, co-morbidities and frailty…

Vaccination of older persons against Sars-Cov-2 and cellular immunogenicity for long term protection (participating in the Doetinchem Cohort Study)

The primary objective is to assess quantitative antibody responses and functional T-cell and memory B-cell responses to SARS-CoV-2 vaccines in blood of older individuals 64-90 years of age at 28 days after the second vaccination. These response will…

an open label, randomised, phase 2 study to evaluate the safety and efficacy of mtl-cebpa administered in combination with sorafenib or sorafenib alone, in TKI naïve participants with previously treated advanced hepatocellular carcinoma (HCC) and hepatitis B or hepatitis C virus (outreach2)

We compare the efficacy and safety of the new medication MTL-CEBPA in combination with sorafenib with the efficacy and safety of sorafenib alone. Sorafenib is already being used for the treatment of HCC.

A Phase 1, Open-Label Study in Healthy Adult Participants to Assess the Pharmacokinetics of JNJ-64281802 Administered as Different Multiple Dose Regimens

In this study we will compare different dosing regimens with the study compound JNJ-64281802. We investigate how quickly and to what extent different doses JNJ-64281802 are absorbed, transported, and eliminated from the body when they are given at…

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of EDP-938 in Non hospitalized Adults with Acute Respiratory Syncytial Virus Infection who are at High Risk for Complications

This study has been transitioned to CTIS with ID 2024-513861-38-00 check the CTIS register for the current data. Primary Objective• To evaluate the effect of EDP-938 compared with placebo on the progression of RSV infection by assessment of clinical…

Study on PhArmacokiNetics of first liNe Antiretrovirals in healthy Breastfeeding volunteers
(PANNA-B PK)

This study has been transitioned to CTIS with ID 2023-510232-36-00 check the CTIS register for the current data. to determine the concentration of currently often used ARV (doravirine, raltegravir, bictegravir, tenofovir alafenamide, emtricitabine)…

A Phase 2 Study to Evaluate Efficacy, Safety and Tolerability of VIR-2218 and VIR-3434 in Participants with Chronic Hepatitis D Virus Infection (SOLSTICE)

This study has been transitioned to CTIS with ID 2024-512203-40-00 check the CTIS register for the current data. The purpose of the study is to evaluate (1) the efficacy of monotherapy and combination VIR-2218 and VIR-3434 therapy in suppressing HDV…

A randomized, blinded, placebo-controlled study to assess the safety, tolerability and pharmacokinetics of EGT710 following administration of single and multiple doses to healthy adults.

The purpose of the study is to see if the study compound (EGT710) is safe and tolerated when given to healthy adults. The study will also look at how the body absorbs, breaks down, and gets rid of the study treatment.Approximately 100 healthy…

A Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Nebulized Bacteriophage Treatment in Outpatient Adult Cystic Fibrosis (CF) Subjects with Chronic Pseudomonas aeruginosa (PsA) Pulmonary Infection

Primary Objective:To evaluate the safety and tolerability of nebulized BX004-A in CF subjects with chronic PsA pulmonary infection.Exploratory Objective:To evaluate the effect of BX004-A on sputum PsA burden, lung function, frequency of APEs, and…

Immunogenicity of HPV-vaccination in a reduced-dose schedule

- To study the kinetics of the vaccine-induced antibody response against HPV16/18 after a two-dose schedule by measuring these antibody responses at approximately 7, 12, 24, 36, 48, 60, 72, 84, 96, 108 and 120 months following the first dose of HPV-…

Effectiveness of computerized training of attention and working memory in Post COVID-19 patients with cognitive complaints

Primary Objective: The aim of this study is to research the effect of a computerized cognitive rehabilitation program (RehaCom) in post COVID-19 patients with cognitive complaints on their sustained and divided attention and their working memory.…

COVID-19 in patients with chronic inflammatory diseases: a prospective cohort study

The primary objective will focus on both the difference in incidence and disease severity of COVID-19 between patients with a chronic inflammatory disease and the control group.

A Randomised Open-Label Trial of Early, Very High-Titre Convalescent Plasma Therapy in Clinically Vulnerable Individuals with Mild COVID-19

To determine whether convalescent plasma collected from donors who have recovered from COVID-19 and who have a very high titre of anti-SARS-CoV-2 antibodies reduce the risk of hospitalization or death due to COVID-19 in patients with early symptoms…